Lifastuzumab vedotin, CAS [[1401812-88-1]]

Produktübersicht

• Artikelname: Lifastuzumab vedotin, CAS [[1401812-88-1]]
• Artikelnummer: MCE-HY-P99705
• Hersteller Artikelnummer: HY-P99705
• Alternativnummer: MCE-HY-P99705-5MG,MCE-HY-P99705-1MG,MCE-HY-P99705-10MG
• Hersteller: MedchemExpress
• Kategorie: Biochemikalien
• Alternative Synonym: RG-7599, DNIB-0600A, NaPi2b-ADC

Produktbeschreibung

Lifastuzumab vedotin (RG-7599, DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. Lifastuzumab vedotin has the potential for non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) research[1].

Produkteigenschaften

• Reinheit: 99.03
• CAS Nummer: [1401812-88-1]
• Target-Kategorie: Antibody-Drug Conjugates (ADCs)

Anwendungsbeschreibung

• Anwendungsbeschreibung: ADC Related